Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
Status:
Completed
Trial end date:
2019-02-12
Target enrollment:
Participant gender:
Summary
This is an open-label treatment program following basic prescribing information for patients
with recurrent UPSC (Uterine Papillary Serous Carcinoma) to provide access to everolimus and
limited treatment alternatives.